The Hepatitis C Drug Developer That Crushed Gilead Sciences, Inc. in 2014 (Hint: It's Not AbbVie)
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 24, 8:03AM CST
For shareholders of Gilead Sciences it's practically been a dream year . Shares rose close to 40%, tacking on roughly $45 billion in market value, following the successful approval and launch of oral hepatitis C drugs Sovaldi and Harvoni. ...
JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)
Hertz and Green Mountain are big market movers
AP - Tue Dec 23, 3:53PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
NBL: 48.50 (-0.48), BB.TO: 12.41 (-0.17), HTZ: 24.38 (-0.09), GMCR: 137.65 (+1.10), OCN: 14.88 (-0.14), NBR: 12.42 (-0.26), VNDA: 14.69 (+1.11), BBRY: 10.67 (-0.13), DRL: 3.38 (-0.02), BZH: 18.59 (+0.03), ENTA: 49.04 (+0.06), BA: 131.24 (+1.21), CELG: 109.60 (+3.48), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), CHK: 19.84 (-0.45), TASR: 26.86 (+0.84)
Enanta Pharmaceuticals (ENTA) Jumps: Stock Rises 10.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 8:39AM CST
Enanta Pharmaceuticals, Inc. (ENTA) shares rose over 10% in the last trading session.
ENTA: 49.04 (+0.06), IG: 9.11 (-0.01)
AbbVie Inc. Throws First Punch in Hep C Price War With Gilead Sciences, Inc.
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 23, 8:19AM CST
What a difference a weekend makes. On Friday, when the Food and Drug Administration approved AbbVie 's Viekira Pak, it looked as if AbbVie had done Gilead Sciences a huge favor pricing its new hepatitis C drug on par with Gilead's Harvoni. ...
ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06)
Enanta Is The Big Winner In The Hepatitis C War Between AbbVie And Gilead
George Rho - at Seeking Alpha - Tue Dec 23, 7:47AM CST
GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06)
Who Is The Devil? Will Gilead Fall Or Soar In 2015?
Pharma Doc - Seeking Alpha - Tue Dec 23, 6:27AM CST
On December 19, 2014, Abbvie's (NYSE: ABBV ) Viekira Pak received US approval for HCV GT1 patients with or without ribavirin with a minimum of 12 weeks of treatment for a cost of $83.3k. As an avid contributor in this area, I wrote a comprehensive...
JNJ: 104.59 (+0.31), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)
Express Scripts' Formulary Changes Create Buying Opportunities For Gilead And Enanta
Clinically Sound Investor - at Seeking Alpha - Tue Dec 23, 6:02AM CST
ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06)
Express Scripts/AbbVie HCV deal should not be surprising
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 8:19AM CST
ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 8:17AM CST
OCN: 14.88 (-0.14), SGOC: 0.61 (-0.02), NVGN: 2.40 (-0.09), EXAS: 27.60 (+0.39), TGE: 2.11 (+0.15), CZR: 15.44 (+0.20), ENTA: 49.04 (+0.06), NQ: 4.32 (-0.36), PVG: 5.07 (+0.14), RDUS: 37.17 (+0.11), CANF: 3.70 (+0.01), NG: 2.82 (+0.10), SYN: 1.46 (-0.07), GILD: 91.29 (+1.84), VSCI: 0.76 (-0.07), CNET: 1.28 (-0.11), SVM: 1.25 (+0.09)
Rewards Outweigh Risk for Long-Term Equity Players: Featured Research on Pier 1 Imports, CarMax, Transocean, Enanta and Aratana
PR Newswire - Mon Dec 22, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Pier 1 Imports (NYSE: PIR), CarMax (NYSE: KMX), Transocean (NYSE: RIG), Enanta (NASDAQ: ENTA), and Aratana (NASDAQ: PETX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
KMX: 67.61 (-0.15), RIG: 18.77 (-0.37), PIR: 15.33 (-0.11), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06)
Stock Futures Point Higher; AbbVie Surges, Gilead Dives
at Investor's Business Daily - Mon Dec 22, 8:10AM CST
Stock futures were steady and positive ahead of Monday's open. Dow futures pointed 82.2 points above fair market value. Nasdaq 100 futures showed weak gains, up 7 points. S&P 500 futures climbed 7.8 points. The stock market today faces mixed...
ESRX: 85.48 (-0.40), CALM: 42.45 (-1.73), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06), WAG: 76.67 (+0.16)
HCV-related firms on the move premarket
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 6:53AM CST
ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06)
FDA approves AbbVie combo hepatitis C treatment
By LINDA A. JOHNSON - AP - Fri Dec 19, 7:32PM CST
TRENTON, N.J. (AP) — Patients with chronic hepatitis C have a new option for treating the liver-damaging virus, with the approval of a combination treatment developed by AbbVie.
JNJ: 104.59 (+0.31), ENTA: 49.04 (+0.06)
Enanta Announces U.S. Food and Drug Administration Approves AbbVie's VIEKIRA PAK(TM) (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C Virus
Business Wire - Fri Dec 19, 4:55PM CST
--In Phase 3 clinical trials, VIEKIRA PAK cured 95-100 percent of hepatitis C patients, with less than two percent of patients experiencing virological failure
ENTA: 49.04 (+0.06)
AbbVie Receives U.S. FDA Approval of VIEKIRA PAK(TM) (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C
PR Newswire - Fri Dec 19, 4:45PM CST
The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE:ABBV) VIEKIRA PAK(TM), an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis. VIEKIRA PAK is the only FDA-approved regimen that contains three distinct mechanisms of action - NS5A inhibitor, NS3/4A protease inhibitor and a non-nucleoside NS5B polymerase inhibitor - that work together to attack the virus at three separate stages of the disease lifecycle to inhibit it from reproducing.
ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06)
Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next
at The Street - Fri Dec 19, 3:16PM CST
U.S. regulators approved a new hepatitis C therapy from Abbvie, heralding a new era of market competition with Gilead Sciences.
GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06)
FDA clears AbbVie HCV combo
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 2:46PM CST
GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06)
PDUFA date approaches for AbbVie HCV combo therapy
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 11:41AM CST
ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Enanta Pharmaceuticals Added to the NASDAQ Biotechnology Index
Business Wire - Mon Dec 15, 7:19AM CST
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that it was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). NASDAQ has announced that the annual re-ranking of the NASDAQ Biotechnology Index will become effective upon market open on December 22, 2014.
ENTA: 49.04 (+0.06)